ReviewInvestigational new drugs1999
Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway.
Review in Investigational new drugs, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Trial
- Trial
- Trial
- Targeted Therapies for the Neurofibromatoses.Cancers · 2021Review
- Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group.Pediatric blood & cancer · 2011Article
- Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia.Biologics : targets & therapy · 2008Article
- Tipifarnib in the treatment of acute myeloid leukemia.Biologics : targets & therapy · 2007Article
- Article
- Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo.Breast cancer research : BCR · 2006Article
- Article
- Investigation of the effect of the farnesyl protein transferase inhibitor R115777 on isoprenylation and intracellular signalling by the prostacyclin receptor.British journal of pharmacology · 2004Article
- Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis.Leukemia · 2003Article
- BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia.Oncogene · 2002Review
- Drug development in pancreatic cancer: finally, biology begets therapy.International journal of gastrointestinal cancer · 2002Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The year 2000 will be a significant date for the field of Ras-related therapies since numerous agents will have Phase II clinical efficacy data maturing to provide proof of principle for this cancer treatment strategy. These data will also provide an important milestone for the cancer research community since these molecules represent a small vanguard of oncology drug discovery projects predicated on molecular targets. We can only hope that these agents are a successful harbinger for the formidable number of targeted therapies that will be entering development pipelines in the coming years.
Indexed as
Identifiers
10665477What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.